Global Blood Therapeutics Inc.

NASDAQ:GBT   3:59:53 PM EDT
36.57
-1.22 (-3.23%)
Products, Strategic Combinations

GBT Expands Sickle Cell Disease Pipeline With Exclusive In-License Of Two Novel Small Molecule Programs From Sanofi S.A.

Published: 03/16/2021 11:13 GMT
Global Blood Therapeutics Inc. (GBT) - Gbt Expands Sickle Cell Disease Pipeline With Exclusive In-license of Two Novel Small Molecule Programs From Sanofi Saglobal Blood Therapeutics - Under Agreement, Gbt Will Conduct All Research, Development, Regulatory and Commercialization Activities Worldwide.
Global Blood Therapeutics - Sanofi Will Receive Upfront Payment & is Entitled to Payments Up to About $353 Million Upon Achievement of Some Milestones.
Global Blood Therapeutics Inc - Sanofi is Also Entitled to Single-digit Tiered Royalties on Worldwide Net Sales.